A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

NCT03018067 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor stopped program\]

Conditions

Hyperkalemia

Interventions

DRUG: RDX227675
DRUG: Placebo

Sponsor

Ardelyx